Nonalcoholic Fatty Liver Disease

Disease State Hub

FDA Alerts

FDA Alert

FDA Approves First Treatment for Adults With NASH, Serious Liver Disease

03/21/2024

Anthony Calabro, MA

The FDA approved resmetirom for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis with moderate-to-advanced liver fibrosis.

03/21/2024

Research Summaries

FDA Alert

FDA Approves First Treatment for Adults With NASH, Serious Liver Disease

03/21/2024

Anthony Calabro, MA

The FDA approved resmetirom for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis with moderate-to-advanced liver fibrosis.

03/21/2024

Research Summary

Guideline Update from the American Diabetes Association for the Detection, Management of Patients With Diabetes, Nonalcoholic Fatty Liver Disease

06/28/2023

Based on recent scientific knowledge, the American Diabetes Association (ADA) released a set of updates including recommendations for the detection and management of nonalcoholic fatty liver disease in...

06/28/2023

research summary

CVD Risk Is Increased in Patients with HIV and NAFLD, Liver Fibrosis

04/26/2023

Leigh Precopio

To better understand the relationship between cardiovascular disease and liver disease in individuals with HIV, researchers examined both traditional risk factors and HIV-specific risk factors of the...

04/26/2023

Obesity

High Prevalence of NAFLD, NASH in Overweight, Obese Populations

12/05/2022

Researchers identified the prevalence of non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH) in individuals who are overweight or obese. ...

12/05/2022

diagnosis and management

AHA Releases First Scientific Statement on NAFLD, ASCVD

04/28/2022

Nonalcoholic fatty liver disease is estimated to occur in 1 in 4 adults worldwide but understanding of the disease and associated complications is lacking. The American Heart Association recently released a...

04/28/2022

April 2024

Current Issue

April 2024

Volume 64

Issue 4